



25th ECNP Congress, 13-17 October 2012, Vienna, Austria

GUIDELINES FOR PAPER SUBMISSION FOR POSTER PRESENTATION

1. GENERAL CONSIDERATIONS

Papers should be prepared according to the following instructions:

1.a Content

- Papers should include:
 - Purpose of the study
 - Methods used
 - Summary of results containing real data and appropriate statistical assessments
 - Conclusions
- Papers must report on high quality original research in the field of neuropsychopharmacology that has not been published whole or in part elsewhere.
- The statements, in particular in the conclusion section, should be balanced.
- No abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Use standard abbreviations for well established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used.
- Please indicate on the paper form the topic of your communication and field of research. You are requested to tick one box only.
- Disclosure statement regarding the paper is requested.

1.b Lay out

- Papers must be submitted in English.
- Papers must be written in Times New Roman, font size 10.
- Type the paper text in single spacing.
- Papers should have a minimum of 450 and a maximum of 500 words.
- The use of underlined and italics is not permitted. Words that need emphasis should be bold type.
- Only one table is allowed, please note that graphs and pictures cannot be included.

1.c References

- No more than three references to previous publications may be included. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2] and [3]. The references should be provided in accordance with the following example:
[1] Spencer, C.M., Wilde, M.I., 1998 Milnacipran. A review of its use in depression. *Drugs* 56, 405-427.

1.d Keywords

- Please select three keywords from the list of keywords. A keyword index will be published in the supplement to the journal *European Neuropsychopharmacology*.

1.e Authors

- Insert the author's name(s) and address(es) of the institution as indicated on the on-line form. Do not add: Prof, Dr, etc.
- State your name as presenting author (first author).

25th ECNP Congress, 13-17 October 2012, Vienna, Austria

2. REVIEW AND PUBLICATION

A paper is eligible for review if registration and full payment has been received before the submission deadline (15 March 2012).

If due to institute regulations you can not pay the registration fee before the outcome of the review of your paper, you can sign a payment declaration and send it to the organising secretariat, declaring that we can charge your credit card once your paper is accepted (July 2012). On the online registration form please click on payment by bank transfer and send in the payment declaration.

If your paper is **not** accepted for publication and/or presentation, you can cancel your registration free of charge within 14 days after receiving the message that your paper has been rejected and the registration fee paid will be returned within 30 days after the outcome.

The papers submitted will be reviewed for:

- Presentation at the congress by means of a poster
- Publication in the congress supplement to the journal *European Neuropsychopharmacology**

**A paper that is not accepted for publication can still be presented at the congress. The titles and authors of these papers will be listed in the poster sessions booklet (to be found in the congress bag) and on the Congress Information System (CIS).*

2.a Review

All submitted papers of which the presenting author has registered will be evaluated by a scientific review committee.. Author(s) will be informed of the committee's decision by e-mail before 1 July 2012. There can be no correspondence about the outcome.

2.b Publication

Papers selected for publication are available on the Congress Information System (CIS), and in a congress supplement to the journal *European Neuropsychopharmacology*. The publisher of *European Neuropsychopharmacology* holds all publication rights including copyright.